PF-06801591 + Bacillus Calmette-Guerin
Phase 3Active 0 watching 0 views this week๐ Rising
76
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Non-muscle Invasive Bladder Cancer
Conditions
Non-muscle Invasive Bladder Cancer
Trial Timeline
Dec 30, 2019 โ Dec 2, 2026
NCT ID
NCT04165317About PF-06801591 + Bacillus Calmette-Guerin
PF-06801591 + Bacillus Calmette-Guerin is a phase 3 stage product being developed by Pfizer for Non-muscle Invasive Bladder Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04165317. Target conditions include Non-muscle Invasive Bladder Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04165317 | Phase 3 | Active |
Competing Products
18 competing products in Non-muscle Invasive Bladder Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG) | AstraZeneca | Phase 3 | 77 |
| Durvalumab + BCG | AstraZeneca | Phase 3 | 77 |
| Durvalumab + Monalizumab | AstraZeneca | Phase 2 | 52 |
| Pembrolizumab + BCG | Merck | Phase 3 | 77 |
| Pembrolizumab | Merck | Phase 1/2 | 41 |
| Sacituzumab tirumotecan + Rescue medication + Supportive care measures | Merck | Phase 1/2 | 41 |
| Eciskafusp Alfa + BCG Medac Strain | Roche | Phase 1 | 33 |
| PF-08052667 + Sasanlimab + BCG + PF-02921367 | Pfizer | Phase 1 | 32 |
| BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 ฮผg/instillation). ) + BCG( 50mg/Instillation) | ImmunityBio | Phase 1/2 | 38 |
| N-803 and BCG + N-803 and Gemcitabine | ImmunityBio | Phase 2 | 49 |
| Cretostimogene Grenadenorepvec | CG Oncology | Phase 2 | 49 |
| Cretostimogene Grenadenorepvec | CG Oncology | Pre-clinical | 20 |
| UGN-301 + UGN-201 + Gemcitabine | UroGen Pharma | Phase 1 | 28 |
| AU-011 | Aura Biosciences | Phase 1 | 25 |
| TARA-002 | Protara Therapeutics | Phase 1 | 25 |
| TARA-002 | Protara Therapeutics | Phase 2 | 44 |
| TARA-002 | Protara Therapeutics | Phase 1 | 25 |
| PD-L1/IDO Peptide Vaccine + Pembrolizumab | IO Biotech | Phase 1 | 25 |